

Korea's Lunit partners with National Cancer Institute to advance AI-powered biomarker research

01 April 2025 | News

To transform cancer treatment and deliver more personalised care to patients worldwide



South Korea-based Lunit, a leading provider of artificial intelligence (AI)-powered solutions for cancer diagnostics and therapeutics, has announced a collaboration with the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH), to explore innovative applications of AI in cancer research.

This collaboration aims to advance research into the tumour microenvironment and immune phenotyping, analysing NCI data to uncover insights that could drive personalised cancer care.

Under the agreement, Lunit tools will be made available to NCI Center for Cancer Research (CCR) investigators, across NCI CCR's portfolio of clinical trials. Lunit will analyse whole-slide images obtained from NCI's clinical studies, using Lunit AI-powered biomarker technologies, including Lunit SCOPE IO and Lunit SCOPE universal IHC. This broad collaboration will enable image-analysis AI to become a core part of cancer research practice.

The two parties plan to jointly prepare publications, presentations, and reports. The primary objective of this partnership is to develop data-driven insights that can help personalise treatment approaches for cancer patients. By applying Lunit's AI solutions across NCI's extensive cancer research portfolio, the collaboration seeks to accelerate discoveries that optimise immunotherapy strategies, improve patient outcomes, and pave the way for more targeted cancer care.